Detalhe da pesquisa
1.
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
N Engl J Med;
378(18): 1671-1680, 2018 May 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29668352
2.
The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial.
Am J Respir Crit Care Med;
202(9): 1237-1243, 2020 11 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32584168
3.
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
Am J Respir Crit Care Med;
201(12): 1508-1516, 2020 06 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32162970
4.
The effect of exacerbation history on outcomes in the IMPACT trial.
Eur Respir J;
55(5)2020 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32299860
5.
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
Respir Res;
21(1): 139, 2020 Jun 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32503599
6.
Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk.
Am J Respir Crit Care Med;
197(1): 47-55, 2018 01 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28737971
7.
Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction.
Am J Respir Crit Care Med;
195(7): 881-888, 2017 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27767328
8.
Misinterpretation of time-to-first event curves can lead to inappropriate treatment.
Eur Respir J;
54(3)2019 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31488584
9.
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis.
ERJ Open Res;
7(1)2021 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33718490
10.
Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT.
Ann Am Thorac Soc;
18(5): 788-798, 2021 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33108212
11.
Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
Chest;
159(3): 985-995, 2021 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33031829
12.
Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
Ther Adv Respir Dis;
14: 1753466620963021, 2020.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33121372
13.
Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study.
Adv Ther;
37(9): 3775-3790, 2020 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32647911
14.
The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
Int J Chron Obstruct Pulmon Dis;
14: 2849-2861, 2019.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31839705
15.
Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.
Respir Med;
131: 27-34, 2017 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28947039
16.
Correction to: Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study.
Adv Ther;
39(3): 1446, 2022 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35060093
17.
Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials.
Respir Med;
112: 65-74, 2016 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26797016
18.
Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease.
Clin Pharmacokinet;
53(7): 637-48, 2014 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24756395
19.
Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.
Chest;
145(5): 981-991, 2014 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24385182
20.
Fluticasone furoate/vilanterol (100/25; 200/25 µg) improves lung function in COPD: a randomised trial.
Respir Med;
107(4): 550-9, 2013 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23332861